GO
Loading...

Enter multiple symbols separated by commas

Pharmaceuticals

More

  • WASHINGTON, May 28- U.S. antitrust regulators have settled a long-running fight with Cephalon, now owned by Teva Pharmaceuticals, over how it resolved a patent infringement lawsuit tied to wakefulness drug Provigil, the Federal Trade Commission said on Thursday. As part of the settlement with regulators, Teva, which bought Cephalon in 2012, agreed to pay $1.2...

  • WASHINGTON, May 28- U.S. antitrust regulators have settled a long-running fight with Cephalon, now owned by Teva Pharmaceuticals, over how it resolved a patent infringement lawsuit over the sleep disorder drug Provigil, the Federal Trade Commission said on Thursday. Cephalon had been accused by the FTC of illegally protecting its monopoly on Provigil by...

  • US high court: California county drug disposal law stands Wednesday, 27 May 2015 | 5:22 PM ET

    OAKLAND, Calif.— The U.S. Supreme Court is letting a Northern California county's drug disposal law stand, paving the way for similar ordinances elsewhere. The court refused to hear the pharmaceutical industry's challenge to an Alameda County program that requires drug companies to pay for the disposal of unused medicines. The law was passed to prevent unused...

  • Paying for a shakeup in cancer drugs   Wednesday, 27 May 2015 | 3:48 PM ET
    Paying for cancer drug performance

    A major drug prescription benefits manager is pushing to change the skyrocketing pricing structure, reports CNBC's Meg Tirrell

  • Two parts of Express Scripts' new plan   Wednesday, 27 May 2015 | 1:01 PM ET
    Two parts of Express Scripts' new plan

    A new plan for Express Scripts regarding cancer drugs, with CNBC's Meg Tirrell.

  • May 27- Drug developer GlobeImmune Inc said its experimental hepatitis B drug did not reduce infection in patients after 24 weeks of treatment in a mid-stage study, sending the company's shares down as much as 60 percent to a record low. GlobeImmune, which is developing the drug with Gilead Sciences Inc, is among several drugmakers looking to tap the demand for...

  • May 27- GlobeImmune Inc said its experimental hepatitis B drug did not meet the main goal of reducing infection in patients after 24 weeks, in a mid-stage trial. GlobeImmune is developing the drug, GS-4774, with Gilead Sciences Inc.. Companies developing hepatitis B drugs include Arrowhead Research Corp, Canada's Tekmira Pharmaceuticals Corp and Isis...

  • Novartis digs into health tech with bet on "robotic pill" Wednesday, 27 May 2015 | 4:01 AM ET

    LONDON, May 27- Swiss drugmaker Novartis is raising its bet on smart technology by collaborating with U.S. start-up Rani Therapeutics on a "robotic pill" for complex biotech drugs that would normally have to be given by injection. Rani said it would run feasibility studies over the next 18-24 months to evaluate how selected Novartis biologic medicines can be...

  • COPENHAGEN, May 26- Bavarian Nordic is hot property after striking two big vaccine deals but the small Danish company is not for sale, despite a wave of consolidation in the healthcare industry, its chief told Reuters. Boosting the immune system is now a top priority for cancer drug companies such as Bristol-Myers, Merck, Roche and AstraZeneca, fuelling renewed...

  • LONDON, May 26- AstraZeneca's hopes of topping $45 billion in revenue by 2023 have been dealt a blow by a problem with an experimental psoriasis drug that the drugmaker had viewed as a potential billion-dollar plus seller. AstraZeneca and Amgen have been sharing development of brodalumab since 2012 as a treatment for psoriasis, psoriatic arthritis and axial...

  • Assuming approval from the U.S. Food and Drug Administration, Amgen Inc. will offer its drug, Repatha, as a biweekly 140 mg injection or a monthly injection of 420 mg, while Praluent, from Regeneron Pharmaceuticals Inc and Sanofi, will be offered in biweekly injections of 75 mg or 150 mg. Regeneron and Sanofi could enjoy a significant pricing advantage with their...

  • May 22- Amgen Inc said it will terminate a collaboration with AstraZeneca Plc to develop a psoriasis drug after it observed suicidal thoughts in the subjects of a trial. AstraZeneca could decide on the development and marketing of the drug for all territories, except for Japan and certain Asian territories, where Kyowa Hakko Kirin has the rights to it, Amgen said.

  • Amgen ends work on experimental psoriasis drug Friday, 22 May 2015 | 5:27 PM ET

    NEW YORK— Drugmakers Amgen and AstraZeneca said Friday that some patients who took an experimental psoriasis drug experienced suicidal thoughts or behavior, and Amgen said it is ending development of the drug. Amgen was in charge of studying brodalumab, a potential treatment for moderate to severe plaque psoriasis and two other inflammatory diseases,...

  • CHICAGO, May 22- Wal-Mart Stores Inc is pressing meat, seafood, dairy and egg suppliers to reduce the use of antibiotics, becoming the first large retailer to take such a public stand against the excessive use of drugs in raising farm animals. Wal-Mart, the country's biggest food retailer, is also telling suppliers not to raise animals in gestation crates or in...

  • Actavis hard switch   Friday, 22 May 2015 | 2:30 PM ET
    Actavis hard switch

    A federal appeals court has made a ruling on a top selling Alzheimer's drug that could make things difficult for drugmaker Actavis, reports CNBC's Meg Tirrell.

  • Wal-Mart urges meat suppliers to curb antibiotic use Friday, 22 May 2015 | 1:42 PM ET

    CHICAGO, May 22- Wal-Mart Stores Inc is pressing meat, seafood, dairy and egg suppliers to reduce the use of antibiotics, becoming the first large retailer to take a stand against the excessive use of drugs in raising farm animals. Wal-Mart, the country's biggest food retailer, is also telling suppliers not to raise animals in gestation crates or in other...

  • Actavis barred from pulling older Alzheimer's drug Friday, 22 May 2015 | 11:19 AM ET
    Actavis Group headquarters is shown in Hafnarfjordur, Iceland, April 20, 2006.

    Actavis cannot pull its top-selling Alzheimer's drug from the market in favor of a pricier version, a federal appeals court ruled.

  • NEW YORK, May 22- Actavis Plc cannot pull its top-selling Alzheimer's drug from the market in favor of a pricier extended-release version, a federal appeals court in New York ruled on Friday. The decision at the 2nd U.S. Circuit Court of Appeals is a win for New York State Attorney General Eric Schneiderman, who sued to block the switch, arguing that Actavis was...

  • NEW YORK, May 22- Actavis Plc cannot pull its top-selling Alzheimer's drug from the market in favor of a pricier extended-release version, a federal appeals court ruled on Friday. A three-judge panel at the 2nd U.S. Circuit Court of Appeals in New York upheld an order by U.S. District Robert Sweet in December requiring Actavis to keep the older drug, Namenda IR, on the...

  • *Seibu tumbles after Cerberus launched selldown. *Skylark dives after news Bain Capital to sell stake. TOKYO, May 22- Japan's Nikkei share average edged down on Friday morning, snapping a five-day winning streak as investors carefully await for the outcome of the Bank Of Japan's two-day policy meeting.